Single or multiple daily doses of aminoglycosides: a meta- analysis

Barza, Michael; Ioannidis, John P. A.; Cappelleri, Joseph C.; Lau, Joseph

doi:10.1136/bmj.312.7027.338

Cited by 415 publications

(234 citation statements)

References 51 publications

Supporting

Mentioning

221

Contrasting

Unclassified

Order By: Relevance

“…For aminoglycosides, this can most easily be attained with once daily dosing (5-7 mg/kg daily gentamicin equivalent). Once-daily dosing yields at least comparable clinical efficacy with possibly decreased renal toxicity compared to multiple daily dosing regimens [141,142]. Once-daily dosing of aminoglycosides is used for patients with preserved renal function.…”

mentioning

confidence: 99%

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

et al. 2017

View full text Add to dashboard Cite

Objective: To provide an update to "Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012". Design:A consensus committee of 55 international experts representing 25 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict-of-interest (COI) policy was developed at the onset of the process and enforced throughout. A stand-alone meeting was held for all panel members in December 2015. Teleconferences and electronic-based discussion among subgroups and among the entire committee served as an integral part of the development. Methods:The panel consisted of five sections: hemodynamics, infection, adjunctive therapies, metabolic, and ventilation. Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles were generated. Each subgroup generated a list of questions, searched for best available evidence, and then followed the principles of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess the quality of evidence from high to very low, and to formulate recommendations as strong or weak, or best practice statement when applicable.

show abstract

mentioning

confidence: 99%

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It is thought that pulse dosing minimises toxicity while reducing treatment failure, morbidity and mortality. Pulse dosing or high-peak-extendedinterval dosing of aminoglycosides was first used by Labowitz et al (1974) in man and it has been accepted that there is no significant difference in safety between pulse dosing and multiple-dose regimes (Galloe et al, 1995;Barza et al, 1996;Ferriols-Lisart and Alós-Almiñana, 1996). Furthermore, efficacy is thought to be superior when using pulse dosing of aminoglycosides (Tran Ba Huy and Deffrennes, 1988;Pettarossi et al, 1990;Campbell et al, 1996).…”

mentioning

confidence: 99%

“…Aminoglycosides are traditionally administered in multiple daily doses (once in every 8 or 12 h) (Baggot, 1981(Baggot, , 1985Frazier, 1988;Barza et al, 1996;Martyn-Jimenez et al, 1998). This scheme often requires pharmacokinetic expertise and close monitoring of drug serum levels and renal function to guide dosage adjustments to maximise efficacy and minimise toxicity (Pettarossi et al, 1990;Magdesian et al, 1998;Tudor et al, 1999).…”

mentioning

confidence: 99%

Pharmacokinetics and renal toxicity of three once-a-day doses of amikacin in cows

López

Gutiérrez

Velázquez

et al. 2005

Acta Veterinaria Hungarica

View full text Add to dashboard Cite

Pharmacokinetic variables of amikacin in cows were determined after administration of amikacin sulphate either intravenously (IV) or intramuscularly (IM) at a dose of 25 mg/kg per day for three days. Amikacin concentrations at time zero and maximum serum concentrations were 240.8 µg/mL and 122.53 µg/mL, respectively. The elimination half-life remained unchanged during the three days of administration (T ½β = 1.33 ± 0.029 h for the IV route and T ½β = 2.75 ± 0.38 h for the IM route). Apparent volumes of distribution suggest limited distribution out of the central compartment (Vd AUC = 0.154 ± 0.005 L/kg; Vd c = 36.50 ± 2.35 L; Vd ss = 0.092 ± 0.004 L/kg). Bioavailability after IM administration was 95%. Serum profiles of urea, creatinine, albumin, electrolytes and pH after 5-day treatment with amikacin at a dose of 25 mg/kg per day IM revealed no changes. Assessment of diffusion of amikacin to milk by a commercially available screening method to detect antibiotic residues revealed that amikacin could not be detected by the fifth milking period after the last treatment. These results suggest that it would be rational to use a large single-daily dose of amikacin for future clinical trials in cows.

show abstract

“…At least eight meta-analyses of clinical trials comparing SDD and MDD of aminoglycosides have been published. [21][22][23][24][25][26][27] Unfortunately, the majority of published studies used in these meta-analyses have methodological flaws and do not permit a definitive assessment of toxicity of SDD vs MDD aminoglycosides. These flaws include small sample size, different aminoglycosides studied, variations in definitions of nephrotoxicity and ototoxicity and failure to account for concurrent use of nephro-and ototoxins.…”

Section: Discussionmentioning

confidence: 99%

Toxicity of single daily dose gentamicin in stem cell transplantation

Warkentin

Ippoliti

Bruton

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:To determine the safety of single daily dose (SDD) gentamicin in recipients of stem cell transplantation (SCT), we evaluated all adult patients at MD Anderson Cancer Center who received SDD gentamicin for treatment of febrile neutropenia. Thirty-three patients received gentamicin 5 mg/kg i.v. every 24 h. Mean duration of therapy was 7 days (range 3-32 days). All patients received vancomycin and 17 received cisplatinum. All patients had normal renal function prior to therapy. Serum gentamicin levels were monitored only when renal function deteriorated. The incidence of nephrotoxicity and clinically significant ototoxicity was 3% and 12%, respectively. All four patients who developed ototoxicity had normal renal function before and during therapy. The mean duration of gentamicin therapy was significantly longer in patients who developed ototoxicity, 20 days vs 9 days (P = 0.001). Patients treated with SDD gentamicin for Ͼ10 days were more likely to develop ototoxicity (P = 0.045). Single daily dosing of gentamicin was associated with clinically significant ototoxicity in 12% of our patients. A larger randomized EORTC trial evaluating SDD vs MDD amikacin failed to detect a difference in ototoxicity. However, the median duration of therapy was only 8 days. The increased incidence of ototoxicity in our study may be due to prolonged therapy, type of aminoglycoside used, concomitant ototoxic agents, small sample size, or a combination of the above.

show abstract

Single or multiple daily doses of aminoglycosides: a meta- analysis

Cited by 415 publications

References 51 publications

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Pharmacokinetics and renal toxicity of three once-a-day doses of amikacin in cows

Toxicity of single daily dose gentamicin in stem cell transplantation

Contact Info

Product

Resources

About